Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Is Moderna Stock Outperforming the Dow?

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart · Mar 4

FDA to offer bonus payments to staffers who complete speedy drug reviews

The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of the schedule

The Independent UK · Feb 26

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts.

The Conversation · Feb 18

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA will drop two-study requirement for new drug approvals, aiming to speed access

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals

The Independent UK · Feb 18

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA shares still aren’t attractive to own in 2026.

Barchart · Feb 18

FDA reverses course and will review Moderna’s mRNA-based flu vaccine

US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’

The Guardian - US · Feb 18

Moderna says the FDA will consider its new flu shot after resolving a public dispute

Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all

The Independent UK · Feb 18

Read news from The Economist, FT, and more,
with one subscription

FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’

Experts say ‘they’re just coming up with reasons’ as agency says application lacked ‘adequate and well controlled’ trial

The Guardian - US · Feb 13

Clinical Trials Show Moderna's New mRNA Flu Vaccine Is Safe and Effective. FDA Won't Even Consider It.

An overzealous government agency suppresses medical innovation yet again.

Reason · Feb 12

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine.

The Conversation · Feb 12

First mRNA vaccine to be produced in UK approved by regulators

The Moderna Innovation and Technology Centre will make millions of cutting-edge mRNA vaccines

The Independent UK · Feb 11

FDA declines to review Moderna application for new flu vaccine

Moderna requests meeting to discuss refusal as decision could have implications for all new and updated vaccines

The Guardian - US · Feb 10

FDA declines to review Moderna’s new flu vaccine

This decision signals heightened scrutiny of vaccines by the FDA under Health Secretary Robert F. Kennedy Jr.

The Independent UK · Feb 10

Can This Former Pandemic Star Make a Stunning Comeback?

Moderna is betting its mRNA pipeline can power the next growth cycle.

Barchart · Feb 9

Get all your
news in one place.

100's of premium titles.
One news app.

Reason · Feb 3

How To Speed Up the Search for Cures Through a Change in Probability Theory

It seems likely the FDA would do well to accept more Bayesian reasoning in medical research.

Barchart · Feb 3

Are Wall Street Analysts Bullish on Moderna Stock?

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

MarketBeat · Jan 29

3 ETFs Catapulting Beyond the S&P to Start the Year

Three ETFs with year-to-date performance of 30% or better include a fund focused on drone technology, one targeting nickel miners, and a covered call play.

Euronews · Jan 21

Promising vaccine for aggressive melanoma could unlock the body’s potential to fight cancer

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Jan 20

Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?

COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?

The Independent UK · Jan 20

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, pharmaceutical companies Moderna and Merck announced in five-year findings.

The Guardian - UK · Jan 9

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

Kiplinger · Dec 19, 2025

Nasdaq Leads as Tech Stages Late-Week Comeback: Stock Market Today

Oracle stock boosted the tech sector on Friday after the company became co-owner of TikTok's U.S. operations.

The Independent UK · Dec 12, 2025

Trump’s FDA plans to put a ‘black box’ warning on COVID vaccines: report

Black boxes are the FDA’s most serious warning sign and are usually placed on opioid products

Barchart · Dec 2, 2025

Is Moderna Stock Underperforming the Nasdaq?

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

Benzinga · Nov 21, 2025

Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today

Despite Nvidia’s strong quarterly performance, the broader market struggled on Thursday. A robust U.S. jobs report, showing non-farm payrolls rising by 119,000 in September, dampened hopes for a December rate cut, as traders now see a 64% chance of the Fed holding rates steady.

1 … 4 5 6 7

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.